Skip to main content
Premium Trial:

Request an Annual Quote

James Glynn, Greg Lucier, James Glover, Stephen Harris, Patrick Berna, Jean-Louis Abitbol, Brigitte Chamayou-Anglade, John Thebault, Chemicon International, Stem Cell Sciences



Invitrogen this week announced that James Glynn, a member of its board of directors and chief executive officer emeritus, will retire as of April 21. Upon his retirement, Invitrogen will reduce its board size from 10 members to nine.

Glynn joined Invitrogen's board and management team in 1998. He served as CFO before becoming interim CEO. He held that position until Greg Lucier became CEO in May 2003. Glynn previously held executive positions at Matrix Pharmaceuticals, Mycogen, and Lubrizol.

Beckman Coulter this week announced that James Glover, senior vice president and CFO, will retire from the company effective June 30. Beckman has started a search for Glover's replacement, the company said.

French drug-discovery firm Trophos announced two new hires and two promotions this week.

Stephen Harris has been appointed chief business officer of Trophos. Harris joins the company after more than 16 years with Glaxo (now GlaxoSmithKline), most recently as director of transactions within worldwide business development. Harris holds a BSc in genetics from the University of Leicester.

Trophos also named Patrick Berna as chief development officer; Jean-Louis Abitbol as chief medical officer; and Brigitte Chamayou-Anglade as chief of regulatory affairs.

Berna has previously been employed by Boehringer-Ingleheim, Pfizer, Parke-Davis, and Jouveinal. He holds a MSc in cell biology from the University of Lille in France, and a PhD in biochemistry from the University of Compiegne in France.

Abitbol previously served as director of clinical research for Trophos and, prior to that, for Pierre Fabre Research Institute. He has also been employed by Cernep-Synthelabo, Jouveinal, Parke-Davis, and Pfizer. He holds an MD from the University Paris VII.

Chamayou-Anglade has served as consultant in regulatory affairs for Trophos since 2002. She has also served as director of regulatory affairs for Laboratoires Chauvin and Laboratoires Fournier. She holds a pharmacy diploma from the University of Montpellier.

Cytomics Systems said this week that it has appointed John Thebault to the newly created position of director of clinical research. Thebault previously was the founder and manager of Aster Cephac, a European CRO specializing in early-stage clinical studies.



Chemicon International and Stem Cell Sciences this week announced the launch of the ESGRO Complete product line for murine embryonic stem cell culture.

The product, developed by SCS's SC Proven division, is the first complete defined medium that enables large-scale, consistent production of mouse ES cells for use in basic research and drug discovery, the companies said.

The product launch follows the establishment of an exclusive deal between the companies signed in November.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.